FBRX
Forte Biosciences, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 43 | +6 | 8.85M | $188.14M | +11 | −5 |
| Q1 2026 | 38 | +5 | 7.04M | $182.49M | +8 | −3 |
| Q4 2025 | 33 | +1 | 5.99M | $163.53M | +3 | −2 |
| Q3 2025 | 11 | +5 | 1.51M | $22.69M | +5 | n/a |
| Q2 2025 | 5 | +1 | 990.17K | $12.80M | +1 | n/a |
| Q1 2025 | 2 | +1 | 74.69K | $579,605 | +1 | n/a |
| Q4 2024 | 1 | 0 | 16.88K | $383,375 | n/a | n/a |
| Q3 2024 | 1 | -3 | 14.27K | $79,930 | n/a | −3 |
| Q2 2024 | 4 | n/a | 528.60K | $283,908 | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 346.29K | n/a | $186,008 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | Renaissance Technologies ✦ | 133.40K | n/a | $71,636 | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Two Sigma Investments ✦ | 40.81K | n/a | $21,916 | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 8.10K | n/a | $4,348 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 40.00K shares, $1,036 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.